COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO WARFARIN FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION  by Lee, Soyon et al.
Arrhythmias
E600
JACC March 27, 2012
Volume 59, Issue 13
COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO WARFARIN FOR STROKE PROPHYLAXIS IN 
ATRIAL FIBRILLATION
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 9:30 a.m.-10:30 a.m.
Session Title: Arrhythmias: AF/SVT: Anticoagulation for Atrial Fibrillation: Warfarin and the Newbies
Abstract Category: 16. Arrhythmias: AF/SVT
Presentation Number: 1235-93
Authors: Soyon Lee, Moise Anglade, Robyn Pisacane, Dan Pham, Jeffrey Kluger, Craig Coleman, The University of Connecticut School of Pharmacy, 
Storrs, CT, USA, The Center for Advanced Cardiovascular Medicine, Greenacres, FL, USA
Background: Rivaroxaban, an oral Factor Xa inhibitor administered once daily without the need for anticoagulation monitoring, was recently 
approved in the United States for the prevention of stroke in patients with atrial fibrillation (AF). The objective of this study was to assess the cost-
effectiveness of rivaroxaban.
Methods: A Markov model was developed to estimate the cost-effectiveness of rivaroxaban 20 mg once daily and adjusted-dose warfarin from 
the Medicare perspective using data from the Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism 
for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial and other published studies of anticoagulation. For the base-
case analysis, we assumed patients with AF were 65-years of age and otherwise healthy, with a CHADS2 score of 2 and no contraindications to 
anticoagulation. Patients were followed for up to 35-years or until death, whichever came first. Evaluated outcomes included costs in 2011 US$, 
quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Costs and outcomes were discounted at 3% per annum. One-
way and probabilistic sensitivity analyses were conducted.
Results: Rivaroxaban treatment resulted in 10.28 QALYs per patient, while adjusted-dose warfarin treatment resulted in 10.07 QALYs. Total 
lifetime costs per patient were $83,415 and $78,160 for rivaroxaban and adjusted-dose warfarin, respectively. The base-case analysis revealed that 
rivaroxaban was cost-effective with the ICER of 25,024 per QALY compared with adjusted-dose warfarin. One-way sensitivity analyses revealed our 
results were most sensitive to changes in the relative risk reduction of ICH and stroke with rivaroxaban, and the cost of rivaroxaban. Monte Carlo 
simulation demonstrated that rivaroxaban was cost-effective in 80% and 91% of 10,000 iterations at willingness-to-pay thresholds of $50,000 and 
$100,000 per QALY.
Conclusions: Our model suggests that rivaroxaban may be a cost-effective alternative to adjusted-dose warfarin in patients with AF who have at 
least a CHADS2score of 2 and no contraindications to anticoagulation.
